AngioGenex (AGGX) 10-K 28 Mar 19 2018 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2018	Mar. 27, 2019	Jun. 30, 2018
FIXED ASSETS [Abstract]
Entity Registrant Name	ANGIOGENEX, INC.
Document Type	10-K
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding		30,386,667
Entity Public Float			$ 4,448,187
Amendment Flag	false
Entity Central Index Key	0001085596
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Well-known Seasoned Issuer	No
Document Period End Date	Dec. 31, 2018
Document Fiscal Year Focus	2018
Document Fiscal Period Focus	FY
Entity Shell Company	false

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($)	Dec. 31, 2018	Dec. 31, 2017
CURRENT ASSETS
Cash	$ 19,583	$ 493,676
Prepaid expenses and taxes receivable	33,236	21,634
TOTAL CURRENT ASSETS	52,819	515,310
TOTAL ASSETS	52,819	515,310
CURRENT LIABILITIES
Accrued expenses	427,974	383,695
Accrued expenses - related parties	417,029	495,536
Notes payable	1,000	11,000
Notes payable - related parties	127,750	127,750
Accrued interest	45,067	51,081
Accrued interest - related parties	77,294	73,321
TOTAL CURRENT LIABILITIES	1,096,114	1,142,383
LONG-TERM LIABILITIES
Notes payable, related parties	27,450	27,450
TOTAL LONG-TERM LIABILITIES	27,450	27,450
TOTAL LIABILITIES	1,123,564	1,169,833
STOCKHOLDERS' DEFICIT
Preferred stock, 5,000,000 shares authorized, $0.001 par value, no shares issued and outstanding	0	0
Common stock, 150,000,000 shares authorized, $0.001 par value, 29,386,667 shares issued and outstanding as of December 30, 2018 and 2017	29,387	29,387
Additional paid-in capital	5,911,585	5,892,359
Accumulated deficit	(7,011,717)	(6,576,269)
TOTAL STOCKHOLDERS' DEFICIT	(1,070,745)	(654,523)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	$ 52,819	$ 515,310

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Dec. 31, 2018	Dec. 31, 2017
Preferred Stock
Preferred stock par value (in Dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in Shares)	5,000,000	5,000,000
Preferred stock, shares issued (in Shares)	0	0
Preferred stock, shares outstanding (in Shares)	0	0
Common Stock
Common stock par value (in Dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in Shares)	150,000,000	150,000,000
Common stock, shares issued (in Shares)	29,386,667	29,386,667
Common stock, shares outstanding (in Shares)	29,386,667	29,386,667

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
EXPENSES
Research and development	$ 30,736	$ 291,336
General and administrative	406,923	354,852
TOTAL OPERATING EXPENSES	437,659	646,188
LOSS FROM OPERATIONS	(437,659)	(646,188)
OTHER INCOME (EXPENSES)
Other income (expense)	312	(768)
Interest Income	711	370
Interest expense, net	(9,958)	(36,443)
TOTAL OTHER INCOME (EXPENSE)	(8,935)	(36,841)
LOSS BEFORE INCOME TAXES	(446,594)	(683,029)
INCOME TAXES (BENEFIT)	(11,146)	0
NET LOSS	$ (435,448)	$ (683,029)
NET LOSS PER COMMON SHARE - BASIC AND DILUTED	$ (.01)	$ (.02)
WEIGHTED AVERAGE NUMBER OF COMMON STOCK SHARES OUTSTANDING - BASIC AND DILUTED	29,386,667	27,761,023

CONSOLIDATED STATEMENTS OF CHAN

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY - USD ($)	Common Stock	Additional Paid-In Capital	Shares Issuable	Accumulated Deficit	Total
Beginning Balance, Amount at Dec. 31, 2016	$ 25,367	$ 5,116,065	$ 1,000	$ (5,893,240)	$ (750,808)
Beginning Balance, Shares at Dec. 31, 2016	25,366,667
Issuance of common stock for settlement of accrued liability, shares	1,000,000
Issuance of common stock for settlement of accrued liability, amount	$ 1,000	0	(1,000)	0	$ 0
Issuance of common stock for services,shares	20,000				3,200
Issuance of common stock for services, amount	$ 20	3,180	0	0	$ 3,200
Sale of common stock, shares	3,000,000
Sale of common stock, amount	$ 3,000	747,000	0	0	750,000
Stock-based compensation		26,114	0	0	26,114
Net Loss				(683,029)	(683,029)
Ending Balance, Amount at Dec. 31, 2017	$ 29,387	5,892,359	0	(6,576,269)	$ (654,523)
Ending Balance, Shares at Dec. 31, 2017	29,386,667
Issuance of common stock for services,shares					0
Stock-based compensation		19,226	0	0	$ 19,226
Net Loss				(435,448)	(435,448)
Ending Balance, Amount at Dec. 31, 2018	$ 29,387	$ 5,911,585	$ 0	$ (7,011,717)	$ (1,070,745)
Ending Balance, Shares at Dec. 31, 2018	29,386,667

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (435,448)	$ (683,029)
Adjustments to reconcile net loss to net cash used in operations:
Issuance of common stock for services rendered - related party	0	3,200
Stock-based compensation - common stock options	$ 19,226	$ 26,114
Changes in operating assets and liabilities:
Increase in prepaid expenses and taxes receivable	17,453	0
Increase (decrease) in accrued expenses	25,528	(34,466)
Increase (decrease) in accrued expenses - related party	(78,507)	127,393
Increase in accrued interest	(6,014)	27,534
Increase in accrued interest - related parties	3,973	4,459
Net cash used by operating activities	(453,789)	(528,795)
CASH FLOWS FROM FINANCING ACTIVITIES
Repayment of notes payable	10,000	0
Repayment of financed insurance premiums	10,304	0
Proceeds from the sale of common stock	0	750,000
Net cash provided by (used in) financing activities	(20,304)	750,000
Net (decrease) increase in cash	(474,093)	221,205
Cash, beginning of period	493,676	272,471
Cash, end of period	19,583	493,676
SUPPLEMENTAL CASH FLOW DISCLOSURES:
Cash paid for interest and income taxes: Interest expense	11,999	4,345
Cash paid for interest and income taxes: Income taxes	0	0
NON-CASH INVESTING AND FINANCING ACTIVITIES:
Insurance premiums financed by a note	$ 29,055	$ 0

NOTE 1 - ORGANIZATION AND DESCR

NOTE 1 - ORGANIZATION AND DESCRIPTION OF BUSINESS	12 Months Ended
	Dec. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
NOTE 1 - ORGANIZATION AND DESCRIPTION OF BUSINESS	NOTE 1 – ORGANIZATION AND DESCRIPTION OF BUSINESS The consolidated financial statements include AngioGenex, Inc., and its wholly owned subsidiary AngioGenex Therapeutics, Inc. AngioGenex, Inc. (“AngioGenex” or the “Company”) was incorporated in the State of New York on March 31, 1999. AngioGenex, Inc. is a bio-pharmaceutical company dedicated to the development and commercialization of a novel treatment for vascular diseases including many forms of cancer, and macular degeneration.

NOTE 2 - LIQUIDITY AND BASIS OF

NOTE 2 - LIQUIDITY AND BASIS OF PRESENTATION	12 Months Ended
	Dec. 31, 2018
Note 2 - Liquidity And Basis Of Presentation
NOTE 2 - LIQUIDITY AND BASIS OF PRESENTATION	NOTE 2 – LIQUIDITY AND BASIS OF PRESENTATION The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As shown in the accompanying financial statements, the Company has incurred substantial net losses since inception. The future of the Company is dependent upon additional financing and revenue to fund its research and development activities and to support operations. However, there is no assurance that the Company will be able to obtain additional financing. Furthermore, there is no assurance that the Food and Drug Administration will grant future approval of the Company’s prospective products or that profitable operations can be attained as a result thereof. The financial statements do not include any recoverability and classification of recorded assets, or the amounts and classification of liabilities that might be necessary in the event the Company cannot continue as a going concern. The Company anticipates that its principal source of funds for the next year will be the issuance of additional equity or debt instruments for cash. Management plans to seek additional capital from new equity securities issuances that will provide funds needed to increase liquidity, fund internal growth and fully implement its business plan. The Company has suffered recurring losses from operations, has negative working capital of $1,043,295, has an accumulated deficit of $7,011,717 as of December 31, 2018 and has no current source of revenues. The estimated working capital requirement for research and development and general and administrative expenditures through March 2020 is approximately $1,300,000. The Company currently has approximately $96,000 available at March 15, 2019. The management estimates, that it will be able to fund current operations through April 2019. Therefore, the Company will need to raise at least $1,204,000 in capital to fund current planned operations through March 2020. The accompanying consolidated financial statements reflect the accounts of the Company and its wholly-owned

NOTE 3 - BASIS OF REPORTING AND

NOTE 3 - BASIS OF REPORTING AND SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Dec. 31, 2018
Accounting Policies [Abstract]
NOTE 3 - BASIS OF REPORTING AND SIGNIFICANT ACCOUNTING POLICIES	NOTE 3 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires the use of management estimates. Such estimates include the determination and establishment of certain accruals and provisions, including income tax. On an ongoing basis, the Company reviews its estimates based upon currently available information. Actual results could differ materially from those estimates. Contingencies Loss contingency provisions are recorded if the potential loss from any claim, asserted or unasserted, or legal proceeding is considered probable and the amount can be reasonably estimated or a range of loss can be determined. These accruals represent management's best estimate of probable loss. Net Loss Per Share Basic loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the periods presented. The computation of diluted loss per share is similar to the computation of basic loss per share, except that the denominator is increased for the assumed exercise of dilutive options and other potentially dilutive securities using the treasury stock method unless the effect is antidilutive. The Company has 11,789,999 and 12,289,999 common stock options outstanding as of December 31, 2018 and 2017, respectively. These options are excluded from the calculations as they are antidilutive due to losses. Reclassifications Certain prior year amounts have been reclassified to conform to current year presentation. These reclassifications had no effect on the reported consolidated losses. Equipment Property, plant and equipment is carried at cost less an allowance for depreciation. Depreciation is recorded using the straight-line method over an estimated useful life of five years. For the years ended December 31, 2018 and 2017, equipment has been fully depreciated and no depreciation expense was recorded. Research and Development Research and development costs primarily consist of payments to consultants and stock based compensation. Stock-based Compensation The Company accounts for stock-based payment awards in accordance with the provisions of Financial Accounting Standards Board (“FASB”) ASC 718, “Compensation—Stock Compensation”, which requires it to recognize compensation expense for all stock-based payment awards made to employees and directors including stock options. The Company issues new shares upon stock option exercises. Stock-based compensation expense recognized is based on the value of the portion of stock-based payment awards that is ultimately expected to vest and has been reduced for estimated forfeitures. The Company values stock-based payment awards at grant date using the Black-Scholes option-pricing model (“Black-Scholes model”). The determination of fair value of stock-based payment awards on the date of grant using an option-pricing model is affected by its stock price as well as assumptions regarding certain variables. These variables include, but are not limited to its expected stock price volatility over the term of the awards and actual and projected stock option exercise behaviors. The Company has elected to account for forfeitures as they occur. Stock-based compensation expense recognized under FASB ASC 718 for the years ended December 31, 2018 and 2017 consisted of stock-based compensation expense related to stock options and was recorded as a component of general and administrative expenses and research and development expenses. The Company follows ASC 505-50 (Equity-Based Payments to Non-employees), which provide guidance in accounting for share-based awards exchanged for services rendered and requires companies to expense the estimated fair value of these awards over the requisite service period. The Company determined the fair value of the stock-based compensation awards granted to non-employees as either the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measurable. The fair value of the equity instruments issued is measured as of the earlier of either of (1) the date at which a commitment for performance by the counterparty to earn the equity instruments is reached, or (2) the date at which the counterparty’s performance is complete. Income Taxes Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to be applied to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance against deferred income tax asset will be recorded if, based on the weight of available evidence, it is more likely than not that some or all of the deferred income tax assets will not be realized. As of December 31, 2018 and 2017, all of the Company’s net deferred income tax assets were subject to a full valuation allowance. The Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that is more than 50% likely of being realized. Changes in recognition are reflected in the period in which the judgement occurs. Recent issued Accounting Pronouncements The Company considers the applicability and impact of all Accounting Standards Updates (“ASUs”) issued by the Financial Accounting Standards Board (the “FASB”). ASUs not discussed below were considered by management and either determined to be not applicable or expected to have minimal impact on our consolidated balance sheets or statements of operations. In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842). The new standard requires that all lessees recognize the assets and liabilities that arise from leases on the balance sheet and disclose qualitative and quantitative information about its leasing arrangements. The new standard will be effective for us on January 1, 2019. The adoption of this standard is not expected to have a material impact on the Company's financial position or results of operations, as the Company has not entered into any lease agreements. In June 2018, FASB issued ASU No. 2018-07 to simplify the accounting for share-based payments to nonemployees by aligning it with the accounting for share-based payments to employees, with certain exceptions. The new guidance expands the scope of Accounting Standards Codification, or ASC, 718 to include share-based payments granted to nonemployees in exchange for goods or services used or consumed in an entity’s own operations and supersedes the guidance in ASC 505-50. The guidance is effective for public business entities in annual periods beginning after December 15, 2018, and interim periods within those annual periods. Early adoption is permitted, including in an interim period for which financial statements have not been issued, but not before an entity adopts ASC 606. The Company has evaluated the effect of adopting this pronouncement as of January 1, 2019, noting no material impact on the Company’s financial position or results of operations upon adoption.

NOTE 4 - AGREEMENT WITH MEMORIA

NOTE 4 - AGREEMENT WITH MEMORIAL SLOAN KETTERING CANCER CENTER	12 Months Ended
	Dec. 31, 2018
Note 4 - Agreement With Memorial Sloan Kettering Cancer Center
NOTE 4 - AGREEMENT WITH MEMORIAL SLOAN KETTERING CANCER CENTER	NOTE 4 – AGREEMENTS WITH MEMORIAL SLOAN KETTERING CANCER CENTER (“MSKCC”) In March 2000, in exchange for $30,000, the Company obtained from MSKCC, a related party, an exclusive worldwide right and license in the field of use, including to make, have made, use, lease, commercialize and sell licensed products and to use licensed processes derived from the invention. In 2014, the Company issued 810,000 shares of common stock in exchange for previously agreed milestone, royalty and sub-license payments. The aforementioned issuance of shares of common stock released the Company from any future obligations and there are no remaining obligations under the agreement. In July 2017 the Company executed a service agreement with MSKCC to provide pre-clinical research services in connection with the development and Investigational New Drug (IND) Application for the Company’s lead compound and its derivatives. The effective date of the agreement is February 2, 2017, and $250,000 of fees and costs have been incurred as of December 31, 2018. The Company paid $150,000 in 2017, $75,000 in 2018 and owes $25,000 as of December 31, 2018, which is included in accrued expenses - related parties in the financial statements.

NOTE 5 - AGREEMENT WITH BIOCHEC

NOTE 5 - AGREEMENT WITH BIOCHECK, INC.	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
NOTE 5 - AGREEMENT WITH BIOCHECK, INC.	NOTE 5 – AGREEMENT WITH BIOCHECK, INC. On December 15, 2003, the Company entered into a development and marketing agreement with BioCheck Inc. for the development and marketing of diagnostic, prognostic, or bio-analytical products. The agreement was modified as of July 21, 2008. Under the agreement, the Company will receive license fees equal to 9% of the gross revenue of the direct sale by BioCheck, Inc. of any products and 25% of any sublicensing revenue received by BioCheck, Inc. As of December 31, 2018 and 2017, no revenues were generated.

NOTE 6 - ACCRUED EXPENSES

NOTE 6 - ACCRUED EXPENSES	12 Months Ended
	Dec. 31, 2018
Payables and Accruals [Abstract]
NOTE 6 - ACCRUED EXPENSES	NOTE 6 – ACCRUED EXPENSES Accrued expenses at December 31, 2018 and 2017 consist of the following: 2018 2017 Research and development expenses $ 185,229 $ 184,866 Professional fees 161,076 116,598 Licenses 50,000 50,000 Other 31,669 32,231 $ 427,974 $ 383,695

NOTE 7 - RELATED PARTY TRANSACT

NOTE 7 - RELATED PARTY TRANSACTIONS	12 Months Ended
	Dec. 31, 2018
Finite-Lived Intangible Assets, Net [Abstract]
NOTE 7 - RELATED PARTY TRANSACTIONS	NOTE 7 – RELATED PARTY TRANSACTIONS The Company owes MSKCC for research and development expenses $25,000 and $100,000 as of December 31, 2018 and 2017, respectively. An officer of the Company allows the Company to use space in his offices for file keeping and other business purposes. The Company pays no rent for this space. This same officer also provides services to the Company in the form of accounting, bookkeeping and tax preparation, for which the Company is billed. As of December 31, 2018 and 2017, the Company owed the officer’s business $159,868 and $163,375, respectively, which is included in accrued expenses – related parties in the financial statements. At December 31, 2018 and 2017, the Company owed a former officer $95,000 for unpaid salary pursuant to an agreement. In addition, two former officers are owed $99,159 for unreimbursed business expenses as of December 31, 2018 and 2017, which is included in accrued expenses - related parties in our financial statements. Two shareholders provide legal services to the Company, for which the Company is billed. As of December 31, 2018 and 2017, the Company owed these shareholders business $38,002, which is included in accrued expenses – related parties in the financial statements.

NOTE 8 - FINANCED INSURANCE PRE

NOTE 8 - FINANCED INSURANCE PREMIUMS	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
NOTE 8 - FINANCED INSURANCE PREMIUMS	NOTE 8 – FINANCED INSURANCE PREMIUMS In August 2018, the Company entered into an agreement to finance $29,055 of its insurance premiums. The agreement provides for monthly repayments of principal and interest accrued at 8.54% per annum, commencing on September 10, 2018. At December 31, 2018, the balance was $18,751 and has been included with accrued expenses in the financial statements.

NOTE 9 - NOTES PAYABLE

NOTE 9 - NOTES PAYABLE	12 Months Ended
	Dec. 31, 2018
Debt Disclosure [Abstract]
NOTE 9 - NOTES PAYABLE	NOTE 9 – NOTES PAYABLE At December 31, 2018 and 2017, the Company’s loans from related parties totaled $155,200 of principal and $77,294 and $73,321 of accrued interest, respectively. The interest rate on these notes vary from 0% to 6%. Related parties include directors, officers, stockholders, and stock option holders. At December 31, 2018 and 2017, the Company’s loans from unrelated parties totaled $1,000 and $11,000 of principal and $786 and $6,800 of accrued interest, respectively. The interest rate on these notes is 6%, and the principal and accrued interest is due on demand. The principal maturity on all of these notes payable are as follows: December 31, 2019 $ 128,750 December 31, 2020 4,700 December 31, 2021 - December 31, 2022 750 Thereafter 22,000 $ 156,200

NOTE 10 - CAPITAL STOCK

NOTE 10 - CAPITAL STOCK	12 Months Ended
	Dec. 31, 2018
Equity [Abstract]
NOTE 10 - CAPITAL STOCK	NOTE 10 – CAPITAL STOCK Common Stock The Company is authorized to issue 150,000,000 shares of $0.001 par value common stock. In July 2017 the Company sold 3,000,000 shares of common stock to related parties at $0.25 per share for proceeds of $750,000. In September 2017 the Company issued 20,000 shares, valued at $3,200, as compensation for services rendered. The expense is included on the consolidated statement of operations for the year ended December 31, 2017. Preferred Stock The Company’s Board of Directors has the authority to issue up to 5.0 million shares of preferred stock with a par value of $0.001 and to determine the price privileges and other terms of the shares. The Board of Directors may exercise this authority without any further approval of stockholders. As of December 31, 2018 and 2017, the Company had no preferred stock issued or outstanding.

NOTE 11 - STOCK OPTIONS

NOTE 11 - STOCK OPTIONS	12 Months Ended
	Dec. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]
NOTE 11 - STOCK OPTIONS	exercise price which is not less than the fair value on date of grant, except that the exercise period of options granted to a stockholder owning more than 10% of the outstanding capital stock may not exceed 5 years with the exercise option price not less than 110% of the fair value of the common stock at date of grant. The options granted vest between 2 and 5 years. At December 31, 2014, the Company increased the number authorized options under the 2004 Plan to 11,954,960. As of December 31, 2018, the plan was terminated and no further options may be granted under this plan. On September 27, 2012, the board of directors and the stockholders of the Company approved a stock option plan (“2012 Plan”), which provides for the initial granting of options to purchase up to 5,000,000 (with a 4% annual increase per year) shares of common stock, pursuant to which officers, directors, advisers and consultants are eligible to receive incentive and/or non-statutory stock options. Each option agreement shall set the terms of the option. However, incentive stock options are limited to an expiration not to exceed 10 years. Under the plan, the exercise price shall not less than the fair value on date of grant, except options granted to a stockholder owning more than 10% of the outstanding capital stock whereby the exercise option price not less than 110% of the fair value of the common stock at date of grant. During the year ended December 31, 2016, the Company granted 600,000 options to consultants and 2,300,000 options to officers. For the years ended December 31, 2018 and 2017, the Company recorded expense of $19,226 and $26,114, respectively, for vested portion of share-based compensation relating to the issuance of these stock options. During 2016, the Company granted 200,000 stock options to a consultant that will vest upon obtaining certain regulatory approval and submission of an IND application to the FDA. These stock options are accounted for as variable performance based option awards and will be adjusted each reporting period to reflect the estimated fair value until such approvals and filings are obtained. The fair value of these options as of December 31, 2018 and 2017 is $18,172 and $32,991, respectively. The change in value of $(14,819) and $(7,930), has been included with stock based compensation for the years ended December 31, 2018 and 2017, respectively. Stock options activity under the plans is summarized as follows: Number of Stock Options Weighted Average Exercise Price Outstanding – December 31, 2016 12,289,999 $ 0.07 Options granted - - Options expired - - Outstanding - December 31, 2017 12,289,999 $ 0.07 Number of Stock Options Weighted Average Exercise Price Outstanding - December 31, 2017 12,289,999 $ 0.07 Options granted - - Options expired (500,000) $ 0.20 Outstanding - December 31, 2018 11,789,999 $ 0.07 Options vested and expected to vest – December 31, 2018 11,514,999 $ 0.07 As of December 31, 2018, no options are available for future grant under the 2004 Plan and 3,890,000 options are available under the 2012 Plan. A summary of the options outstanding and exercisable as of December 31, 2018 is as follows: Weighted Weighted Average Number of Average Remaining Aggregate Stock Exercise Contractual Intrinsic Options Price Life in Years Value Options outstanding 11,789,999 $0.07 1.87 $1,544,800 Options vested and expected to vest 11,514,999 $0.07 1.86 $1,511,800 The following table summarizes information regarding outstanding stock option grants as of December 31, 2018: Outstanding Exercisable Range of Exercise Prices Granted Stock Options Outstanding Weighted- Average Remaining Contractual Life (Years) Weighted- Average Exercise Price Granted Stock Options Exercisable Weighted- Average Exercise Price $ 0.01-0.05 6,659,999 1.85 $ 0.04 6,659,999 $ 0.04 0.08-0.10 3,570,000 2.38 0.08 3,295,000 0.08 0.17 1,560,000 0.80 0.17 1,560,000 0.17 $ 0.01-0.17 11,789,999 1.87 $ 0.07 11,514,999 $ 0.07 The following is a summary of the status of the Company's non-vested stock options as of December 31, 2017 and the changes during the year ended December 31, 2017: Weighted Number of Average Stock Grant-Date Nonvested Stock Options Options Fair Value Nonvested as of January 1, 2017 875,000 $0.08 Granted - - Vested 300,000 $ 0.08 Forfeited - - Nonvested as of December 31, 2017 575,000 $0.08 The following is a summary of the status of the Company's non-vested stock options as of December 31, 2018 and the changes during the year ended December 31, 2018: Weighted Number of Average Stock Grant-Date Nonvested Stock Options Options Fair Value Nonvested as of January 1, 2018 575,000 $ 0.08 Granted - - Vested 300,000 $ 0.08 Forfeited - - Nonvested as of December 31, 2018 275,000 $0.08 The Company did not grant any stock options during the year ended December 31, 2018. On January 15, 2019 the company granted 3,825,000 options to members of the Board of Directors. The options are fully vested upon grant, exercisable at $0.35 and expire in 5 years.

NOTE 12 - INCOME TAXES

NOTE 12 - INCOME TAXES	12 Months Ended
	Dec. 31, 2018
Income Tax Disclosure [Abstract]
NOTE 12 - INCOME TAXES	NOTE 12 — INCOME TAXES There was no income tax (benefit) expense for the years ended December 31, 2018 and 2017. On December 22, 2017, the bill known as the “Tax Cut and Jobs Act” (the “Act”) was signed into law. The Act, which became effective with respect to most of its provisions as of January 1, 2018, significantly revises U.S. corporation tax laws by, among other things, reducing the U.S. federal corporate income tax rate from 34% to 21%, changing the taxation of foreign earnings (including taxation of certain global intangible low-taxed income (“GILTI”)), allowing immediate expensing for qualified assets, repealing deduction for domestic manufacturing, and imposing further limitations on the deductibility of executive compensation. As a result of the Act being signed into law the Company adjusted its deferred tax assets in the fourth quarter of 2017 related to the re-measurement of its US deferred tax assets before valuation allowance at the lower enacted corporate tax rates. The effect of this remeasurement of $574,000 has been included in the 2017 columns of the tables below. Income tax benefit was computed by applying the United States federal statutory rate of 21% for 2018 and 34% for 2017 to net loss before taxes as follows: 2018 2017 United States federal income tax rate 21.00 % 34.00 % State income tax, net of federal benefit 13.55 11.32 Change in federal tax rate - (84.06) Permanent differences (0.10) (0.06) Other (2.27) (1.67) Expiration of stock options (5.40) - Federal tax credit 4.79 3.10 Change in valuation allowance (31.57) 37.37 Effective tax rate 0.00 % 0.00 % Significant components of the Company’s deferred tax assets and (liabilities) are as follows: Year Ended December 31, 2018 2017 Deferred tax assets: Federal net operating loss carryforwards $ 603,000 $ 519,000 State and local net operating loss carry forward 388,000 334,000 Share based payments 232,000 249,000 Accounts payable and accrued expenses 201,000 238,000 Federal and local tax credits 118,000 107,000 Capitalized research and development 501,000 454,000 Accrued interest 42,000 43,000 Deferred tax asset 2,085,000 1,944,000 Valuation allowance (2,085,000) (1,944,000) Total deferred tax assets $ - $ - The Company has evaluated the available evidence supporting the realization of its gross deferred tax assets, including the amount and timing of future taxable income, and has determined that it is more likely than not that the deferred tax assets will not be realized. Due to such uncertainties surrounding the realization of the deferred tax assets, the Company maintains a valuation allowance of $2,085,000 and $1,944,000 against all of its deferred tax assets as of December 31, 2018 and 2017, respectively. For the years ended December 31, 2018 and 2017, the total change in valuation allowance was $141,000 and $(255,000), respectively. Realization of the deferred tax assets will be primarily dependent upon the Company's ability to generate sufficient taxable income. At December 31, 2018 and 2017, the Company had net operating loss carryforwards of approximately $2,873,000 and $2,471,000 for federal income tax purposes, and $2,870,000 and $2,468,000 for each state and local income tax purposes, respectively. Federal and state net operating loss carryforwards expire through 2038. The state net operating losses are attributable to New York. In addition, the Company has research and development credits for federal and local income tax purposes of approximately $118,000 and $107,000, respectively, which will begin to expire in 2021. Under Section 382 of the Internal Revenue Code of 1986, as amended, or the IRC, substantial changes in our ownership may limit the amount of net operating loss and research and development income tax credit carryforwards that could be utilized annually in the future to offset taxable income. Specifically, this limitation may arise in the event of a cumulative change in ownership of our company of more than 50% within a three-year period. Any such annual limitation may significantly reduce the utilization of the net operating loss carryforwards before they expire. Since the Company's formation, the Company has raised capital through the issuance of capital stock on several occasions which, combined with the purchasing stockholders' subsequent disposition of those shares, may have resulted in such an ownership change, or could result in an ownership change in the future upon subsequent disposition. The Company intends to complete a study in the future to assess whether an ownership change has occurred or whether there have been multiple ownership changes since the Company's formation. The Company did not have any unrecognized tax positions for the years ended December 31, 2018 and 2017. We recognize interests and/or penalties related to income tax matters in income tax expense. We did not recognize any accrued interest and penalties related to unrecognized tax benefits related to the years ended December 31, 2018 and 2017.

NOTE 13 - COMMITMENTS AND CONTI

NOTE 13 - COMMITMENTS AND CONTINGENCIES	12 Months Ended
	Dec. 31, 2018
Commitments and Contingencies Disclosure [Abstract]
NOTE 13 - COMMITMENTS AND CONTINGENCIES	NOTE 13 — COMMITMENTS AND CONTINGENCIES In July 2006, Comparative Biosciences Inc. (“CompBio”) , a company that AngioGenex hired to breed and house a colony of its proprietary “Id-Knockout” mice, sued the Company claiming approximately $200,000 in unpaid invoices. AngioGenex’s response included counter-claims for CompBio’s breaches of contract, as well as a number of business torts. On November 6, 2007, the parties agreed to a disposition of the suit under a stipulated judgment and settlement agreement pursuant to which: CompBio must return the laboratory mice and all scientific data from the research, CompBio agreed to forego all intellectual property rights in the mice and in the research that it acknowledged belong to AngioGenex, and AngioGenex agreed to pay CompBio $55,000 in installments over a 5-year period, plus accumulated interest at 5% per annum. The stipulated judgment and settlement agreement was filed with the court in November 2007. The Company has not made the required payments since the fourth quarter of 2008, and is in default of this settlement agreement. Under the terms of the agreement, upon receipt of written notification of default from CompBio the Company has five days to cure. Failure by the Company to cure the default results in an increase in the settlement amount to $75,000 plus retroactive interest of 5% on the balance. The Company has not received any notification of default from CompBio as of report date. In November 2007 and various dates in 2008, the Company has made $17,500 payments to CompBio pursuant to the settlement agreement, and had accrued interest of $44,281. Since those dates, no payments have been made.

NOTE 14 - SUBSEQUENT EVENTS

NOTE 14 - SUBSEQUENT EVENTS	12 Months Ended
	Dec. 31, 2018
Subsequent Events [Abstract]
NOTE 14 - SUBSEQUENT EVENTS	NOTE 14 — SUBSEQUENT EVENTS In January 2019, the Company sold to a private investor 1,000,000 shares of common stock at $0.20 per share for proceeds of $200,000.

NOTE 3 - BASIS OF REPORTING A_2

NOTE 3 - BASIS OF REPORTING AND SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
	Dec. 31, 2018
Accounting Policies [Abstract]
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires the use of management estimates. Such estimates include the determination and establishment of certain accruals and provisions, including income tax. On an ongoing basis, the Company reviews its estimates based upon currently available information. Actual results could differ materially from those estimates.
Contingencies	Contingencies Loss contingency provisions are recorded if the potential loss from any claim, asserted or unasserted, or legal proceeding is considered probable and the amount can be reasonably estimated or a range of loss can be determined. These accruals represent management's best estimate of probable loss.
Reclassifications	Reclassifications Certain prior year amounts have been reclassified to conform to current year presentation. These reclassifications had no effect on the reported consolidated losses.
Commitments and Contingencies	Contingencies Loss contingency provisions are recorded if the potential loss from any claim, asserted or unasserted, or legal proceeding is considered probable and the amount can be reasonably estimated or a range of loss can be determined. These accruals represent management's best estimate of probable loss.
Net Loss Per Share	Net Loss Per Share Basic loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the periods presented. The computation of diluted loss per share is similar to the computation of basic loss per share, except that the denominator is increased for the assumed exercise of dilutive options and other potentially dilutive securities using the treasury stock method unless the effect is antidilutive. The Company has 11,789,999 and 12,289,999 common stock options outstanding as of December 31, 2018 and 2017, respectively. These options are excluded from the calculations as they are antidilutive due to losses.
Equipment	Equipment Property, plant and equipment is carried at cost less an allowance for depreciation. Depreciation is recorded using the straight-line method over an estimated useful life of five years. For the years ended December 31, 2018 and 2017, equipment has been fully depreciated and no depreciation expense was recorded.
Research and Development	Research and Development Research and development costs primarily consist of payments to consultants and stock based compensation.
Stock-based Compensation	Stock-based Compensation The Company accounts for stock-based payment awards in accordance with the provisions of Financial Accounting Standards Board (“FASB”) ASC 718, “Compensation—Stock Compensation”, which requires it to recognize compensation expense for all stock-based payment awards made to employees and directors including stock options. The Company issues new shares upon stock option exercises. Stock-based compensation expense recognized is based on the value of the portion of stock-based payment awards that is ultimately expected to vest and has been reduced for estimated forfeitures. The Company values stock-based payment awards at grant date using the Black-Scholes option-pricing model (“Black-Scholes model”). The determination of fair value of stock-based payment awards on the date of grant using an option-pricing model is affected by its stock price as well as assumptions regarding certain variables. These variables include, but are not limited to its expected stock price volatility over the term of the awards and actual and projected stock option exercise behaviors. The Company has elected to account for forfeitures as they occur. Stock-based compensation expense recognized under FASB ASC 718 for the years ended December 31, 2018 and 2017 consisted of stock-based compensation expense related to stock options and was recorded as a component of general and administrative expenses and research and development expenses. The Company follows ASC 505-50 (Equity-Based Payments to Non-employees), which provide guidance in accounting for share-based awards exchanged for services rendered and requires companies to expense the estimated fair value of these awards over the requisite service period. The Company determined the fair value of the stock-based compensation awards granted to non-employees as either the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measurable. The fair value of the equity instruments issued is measured as of the earlier of either of (1) the date at which a commitment for performance by the counterparty to earn the equity instruments is reached, or (2) the date at which the counterparty’s performance is complete.
Income Taxes	Income Taxes Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to be applied to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance against deferred income tax asset will be recorded if, based on the weight of available evidence, it is more likely than not that some or all of the deferred income tax assets will not be realized. As of December 31, 2018 and 2017, all of the Company’s net deferred income tax assets were subject to a full valuation allowance. The Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that is more than 50% likely of being realized. Changes in recognition are reflected in the period in which the judgement occurs.
Recent Issued Accounting Pronouncements	Recent issued Accounting Pronouncements The Company considers the applicability and impact of all Accounting Standards Updates (“ASUs”) issued by the Financial Accounting Standards Board (the “FASB”). ASUs not discussed below were considered by management and either determined to be not applicable or expected to have minimal impact on our consolidated balance sheets or statements of operations. In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842). The new standard requires that all lessees recognize the assets and liabilities that arise from leases on the balance sheet and disclose qualitative and quantitative information about its leasing arrangements. The new standard will be effective for us on January 1, 2019. The adoption of this standard is not expected to have a material impact on the Company's financial position or results of operations, as the Company has not entered into any lease agreements. In June 2018, FASB issued ASU No. 2018-07 to simplify the accounting for share-based payments to nonemployees by aligning it with the accounting for share-based payments to employees, with certain exceptions. The new guidance expands the scope of Accounting Standards Codification, or ASC, 718 to include share-based payments granted to nonemployees in exchange for goods or services used or consumed in an entity’s own operations and supersedes the guidance in ASC 505-50. The guidance is effective for public business entities in annual periods beginning after December 15, 2018, and interim periods within those annual periods. Early adoption is permitted, including in an interim period for which financial statements have not been issued, but not before an entity adopts ASC 606. The Company has evaluated the effect of adopting this pronouncement as of January 1, 2019, noting no material impact on the Company’s financial position or results of operations upon adoption.

NOTE 6 - ACCRUED EXPENSES (Tabl

NOTE 6 - ACCRUED EXPENSES (Tables)	12 Months Ended
	Dec. 31, 2018
Payables and Accruals [Abstract]
Accrued Expenses	2018 2017 Research and development expenses $ 185,229 $ 184,866 Professional fees 161,076 116,598 Licenses 50,000 50,000 Other 31,669 32,231 $ 427,974 $ 383,695

NOTE 9 - NOTES PAYABLE (Tables)

NOTE 9 - NOTES PAYABLE (Tables)	12 Months Ended
	Dec. 31, 2018
Debt Disclosure [Abstract]
Principle maturity on notes payable	December 31, 2019 $ 128,750 December 31, 2020 4,700 December 31, 2021 - December 31, 2022 750 Thereafter 22,000 $ 156,200

NOTE 11 - STOCK OPTIONS (Tables

NOTE 11 - STOCK OPTIONS (Tables)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]
Stock options activity	Number of Stock Options Weighted Average Exercise Price Outstanding - December 31, 2017 12,289,999 $ 0.07 Options granted - - Options expired (500,000) $ 0.20 Outstanding - December 31, 2018 11,789,999 $ 0.07 Options vested and expected to vest – December 31, 2018 11,514,999 $ 0.07	Number of Stock Options Weighted Average Exercise Price Outstanding – December 31, 2016 12,289,999 $ 0.07 Options granted - - Options expired - - Outstanding - December 31, 2017 12,289,999 $ 0.07
Options outstanding and exercisable	Weighted Weighted Average Number of Average Remaining Aggregate Stock Exercise Contractual Intrinsic Options Price Life in Years Value Options outstanding 11,789,999 $0.07 1.87 $1,544,800 Options vested and expected to vest 11,514,999 $0.07 1.86 $1,511,800
Outstanding stock option grants	Outstanding Exercisable Range of Exercise Prices Granted Stock Options Outstanding Weighted- Average Remaining Contractual Life (Years) Weighted- Average Exercise Price Granted Stock Options Exercisable Weighted- Average Exercise Price $ 0.01-0.05 6,659,999 1.85 $ 0.04 6,659,999 $ 0.04 0.08-0.10 3,570,000 2.38 0.08 3,295,000 0.08 0.17 1,560,000 0.80 0.17 1,560,000 0.17 $ 0.01-0.17 11,789,999 1.87 $ 0.07 11,514,999 $ 0.07
Non-vested stock options	Weighted Number of Average Stock Grant-Date Nonvested Stock Options Options Fair Value Nonvested as of January 1, 2018 575,000 $ 0.08 Granted - - Vested 300,000 $ 0.08 Forfeited - - Nonvested as of December 31, 2018 275,000 $0.08	Weighted Number of Average Stock Grant-Date Nonvested Stock Options Options Fair Value Nonvested as of January 1, 2017 875,000 $0.08 Granted - - Vested 300,000 $ 0.08 Forfeited - - Nonvested as of December 31, 2017 575,000 $0.08

NOTE 12 - INCOME TAXES (Tables)

NOTE 12 - INCOME TAXES (Tables)	12 Months Ended
	Dec. 31, 2018
Income Tax Disclosure [Abstract]
Income tax benefit	2018 2017 United States federal income tax rate 21.00 % 34.00 % State income tax, net of federal benefit 13.55 11.32 Change in federal tax rate - (84.06) Permanent differences (0.10) (0.06) Other (2.27) (1.67) Expiration of stock options (5.40) - Federal tax credit 4.79 3.10 Change in valuation allowance (31.57) 37.37 Effective tax rate 0.00 % 0.00 %
Significant components of the Company's deferred tax assets and (liabilities)	Year Ended December 31, 2018 2017 Deferred tax assets: Federal net operating loss carryforwards $ 603,000 $ 519,000 State and local net operating loss carry forward 388,000 334,000 Share based payments 232,000 249,000 Accounts payable and accrued expenses 201,000 238,000 Federal and local tax credits 118,000 107,000 Capitalized research and development 501,000 454,000 Accrued interest 42,000 43,000 Deferred tax asset 2,085,000 1,944,000 Valuation allowance (2,085,000) (1,944,000) Total deferred tax assets $ - $ -

NOTE 2 - LIQUIDITY AND BASIS _2

NOTE 2 - LIQUIDITY AND BASIS OF PRESENTATION (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Note 2 - Liquidity And Basis Of Presentation
Accumulated deficit		$ (7,011,717)	$ (6,576,269)
Negative working capital		$ 1,043,295
estimated working capital requirement	$ 1,300,000

NOTE 3 - SUMMARY OF SIGNIFICANT

NOTE 3 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Accounting Policies [Abstract]
Minimum estimated useful life of property and equipment	5 years
Maximum estimated useful life of property and equipment	5 years
Stock issued for services, value		$ 3,200

NOTE 4 - AGREEMENT WITH MEMOR_2

NOTE 4 - AGREEMENT WITH MEMORIAL SLOAN KETTERING CANCER CENTER (Details) - USD ($)	1 Months Ended	12 Months Ended	20 Months Ended
	Mar. 31, 2000	Dec. 31, 2014	Sep. 30, 2018
Note 4 - Agreement With Memorial Sloan Kettering Cancer Center
MSKCC right and license fee	$ 30,000
MSKCC service agreement fees and costs			$ 250,000
Shares of common stock issued to MSKCC in exchange for previously agreed milestone, royalty and sub-license payments		810,000

NOTE 5 - AGREEMENT WITH BIOCH_2

NOTE 5 - AGREEMENT WITH BIOCHECK, INC. (Details Narrative)	Jul. 21, 2008
Notes to Financial Statements
Percent license fee of gross revenue owed to Angiogenex	9.00%
Percent sublicensing revenue owed to Angiogenex	25.00%

NOTE 6 - ACCRUED EXPENSES - Acc

NOTE 6 - ACCRUED EXPENSES - Accrued Expenses (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Payables and Accruals [Abstract]
Research and development expenses	$ 185,229	$ 184,866
Professional fees	161,076	116,598
Licenses	50,000	50,000
Other	31,669	32,231
Accured Expenses Total	$ 427,974	$ 383,695

NOTE 7 - RELATED PARTY TRANSA_2

NOTE 7 - RELATED PARTY TRANSACTIONS (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Finite-Lived Intangible Assets, Net [Abstract]
Owed to MSKCC for research and development expenses	$ 25,000	$ 100,000
Owed to related party business	159,868	163,375
Unpaid salary owed to former officer	95,000	95,000
Owed reimbursed business expenses	99,159	99,159
Legal service fees owed to related party	$ 38,002	$ 38,002

NOTE 8 - FINANCED INSURANCE P_2

NOTE 8 - FINANCED INSURANCE PREMIUMS (Details Narrative) - USD ($)	1 Months Ended	12 Months Ended
	Aug. 31, 2018	Dec. 31, 2018	Dec. 31, 2017
Notes to Financial Statements
Amount of insurance premium financed	$ 29,055	$ 29,055	$ 0
Rate of insurance interest accrued per annum	8.54%
Balance due on Insurance premium		$ 18,751

NOTE 9 - NOTES PAYABLE - PRINCI

NOTE 9 - NOTES PAYABLE - PRINCIPLE MATURITY ON NOTES PAYABLE (Details) - USD ($)	60 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Debt Disclosure [Abstract]
Principle maturity	$ 22,000	$ 750	$ 0	$ 4,700	$ 128,750
Principle maturity total	$ 156,200

NOTE 9 - NOTES PAYABLE (Details

NOTE 9 - NOTES PAYABLE (Details Narrative) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Debt Disclosure [Abstract]
Loans from related parties- principle	$ 155,200
Loans from related parties- interest	$ 77,294	$ 73,321
Max interest rate on related party loans	6.00%
Min interest rate on related party loans	0.00%
Unrelated Party Note total	$ 1,000	11,000
Interest accrued on unrelated party advance	$ 786	$ 6,800
Interest rate on unrelated party advance	6.00%

NOTE 10 - CAPITAL STOCK (Detail

NOTE 10 - CAPITAL STOCK (Details Narrative) - USD ($)	1 Months Ended			12 Months Ended
	Jan. 31, 2019	Sep. 30, 2017	Jul. 31, 2017	Dec. 31, 2018	Dec. 31, 2017
Equity [Abstract]
Common stock, Authorized				150,000,000	150,000,000
Shares issued for cash, duration	1,000,000		3,000,000
Price per share, duration	$ .20		$ .025
Cash paid for shares, duration	$ 200,000		$ 750,000	$ 0	$ 750,000
Shares issued for services		20,000		0	3,200
Value of shares issued for services		$ 3,200
Preferred shares outstanding				0	0

NOTE 11 - STOCK OPTIONS (Detail

NOTE 11 - STOCK OPTIONS (Details)	Dec. 31, 2018$ / sharesshares
Exercise Price $0.01-0.05
Stock Options - Number Outstanding | shares	6,659,999
Stock Options Outstanding - Average Remaining Contractual Life (in years)	1 year 10 months
Stock Options Outstanding - Weighted Average Exercise Price | $ / shares	$ .04
Stock Options - Number Exercisable | shares	6,659,999
Stock Options Exercisable - Weighted Average Exercise Price | $ / shares	$ 0.04
Exercise Price $0.08-0.10
Stock Options - Number Outstanding | shares	3,570,000
Stock Options Outstanding - Average Remaining Contractual Life (in years)	2 years 4 months
Stock Options Outstanding - Weighted Average Exercise Price | $ / shares	$ .08
Stock Options - Number Exercisable | shares	3,295,000
Stock Options Exercisable - Weighted Average Exercise Price | $ / shares	$ 0.08
Exercise Price $0.17
Stock Options - Number Outstanding | shares	1,560,000
Stock Options Outstanding - Average Remaining Contractual Life (in years)	8 months
Stock Options Outstanding - Weighted Average Exercise Price | $ / shares	$ .17
Stock Options - Number Exercisable | shares	1,560,000
Stock Options Exercisable - Weighted Average Exercise Price | $ / shares	$ 0.17
Exercise Price $0.01-0.17
Stock Options - Number Outstanding | shares	11,789,999
Stock Options Outstanding - Average Remaining Contractual Life (in years)	1 year 10 months
Stock Options Outstanding - Weighted Average Exercise Price | $ / shares	$ .17
Stock Options - Number Exercisable | shares	11,514,999
Stock Options Exercisable - Weighted Average Exercise Price | $ / shares	$ 0.17

NOTE 11 - STOCK OPTIONS (Deta_2

NOTE 11 - STOCK OPTIONS (Details Narrative)	12 Months Ended
	Dec. 31, 2018shares
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]
Stock Options Granted	0
Stock Options Available	3,890,000

NOTE 13 - COMMITMENTS AND CON_2

NOTE 13 - COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)	131 Months Ended
	Sep. 30, 2018	Dec. 31, 2018	Nov. 06, 2007
Commitments and Contingencies Disclosure [Abstract]
Settlement Agreement amount owed			$ 55,000
Interest rate on settlement agreement, per annum	5.00%
Settlement Agreement payments made	$ 17,500
Settlement Agreement accrued interest		$ 44,281

NOTE 14 - SUBSEQUENT EVENTS (De

NOTE 14 - SUBSEQUENT EVENTS (Details Narrative) - USD ($)	1 Months Ended		12 Months Ended
	Jan. 31, 2019	Jul. 31, 2017	Dec. 31, 2018	Dec. 31, 2017
Subsequent Events [Abstract]
Shares issued for cash, duration	1,000,000	3,000,000
Price per share, duration	$ .20	$ .025
Cash paid for shares, duration	$ 200,000	$ 750,000	$ 0	$ 750,000